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Venous thromboembolism (VTE) is the condition 
in which blood clots form within the venous 
circulatory system, and consist of DVT (deep vein 
thrombosis) and PEs (Pulmonary emboli).   
It is a common condition, with an estimated life-
time risk of 8% and an annual incidence of 0.84-1 
per 1000 population1, 2 and represents a 
significant economic burden: within Australia the 
annual estimated cost in 2018 being $1.72 billion 
AUD3.  
The condition is considered aeromedically 
significant for both aircrew and passengers; 
diagnosis and treatment may have implications on 
an aviators medical certificate and the general 
public are often concerned about developing 
“economy class syndrome”. 
This paper reviews the pathophysiology of VTE, 
the relationship between VTE and its treatment in 
the aviation environment.  It also reviews some of 
the international aeromedical regulatory 
guidelines and provides a suggested approach to 
certification in case of VTE. 
 
PATHOPHYSIOLOGY 
Venus thromboembolism typically results form a 
combination of factors known as Virchows triad; 
venous stasis, endothelial injury and 
hypercoagulability. These predisposing factors lead 
to development of thrombus from activation of the 
clotting cascade4. 
Risk factors include: 
• Older age 
• Obesity 
• Previous history/Family history of VTE 
• Antiphospholipid syndrome/Thrombophilia 
• Active cancer 
• Recent immobilisation/travel/surgery 
 
• Pregnancy/post-partum 
• Oestrogen therapy (hormone replacement 
therapy and oral contraceptive pill) 
 
The clinical presentation of VTE is dependent on the 
location of the thrombosis and may be non-specific, 
generally the signs and symptoms include: 
Deep vein thrombosis – peripheral oedema, 
unilateral limb pain and erythema. 
Pulmonary embolism – chest pain, dyspnoea, 
haemoptysis, tachycardia and syncope.  
Long-term morbidity includes pulmonary 
hypertension and post-thrombotic syndrome. Post-
thrombotic syndrome is common and is estimated to 
occur in 1 in 3 patients following a DVT5. 
 
TREATMENT 
Treatment of VTE is usually with anticoagulation 
therapy. The choice and duration of treatment is 
dependent on location and the presence of risk 
factors (whether it was provoked or unprovoked). 
Recommended treatment duration is from between 3-
6 months however, therapy may continue life-long if 
there is a risk of recurrence. 
A provoked VTE occurs in the presence of either a 
transient risk factors such as pregnancy, post-
partum, surgery immobility or oestrogen therapy 
(menopause therapy or oral contraceptive pill) or a 
persistent risk factor, such as are an inherited 
thrombophilia or palliative malignancy. 
A provoked VTE caused by a transient risk factor is 
usually considered favourable and will usually require 
a shorter duration of treatment.  
Another important factor when considering treatment 
duration is the location of the VTE.  
A distal DVT is one located below the knee, and 
confined to the calf veins and will result in a shorter 









Direct oral anticoagulants/Novel oral anticoagulants 
are non-vitamin K antagonists are considered first-
line for treatment due to their safety profile and work 
by blocking factors within the clotting casacade. 
Within Australia rivaroxaban, apixaban and 
dabigatran are the most common NOACs used.  
• Warfarin 
Warfarin blocks hepatic synthesis of enzymes used 
in the reactivation of Vitamin K thereby inhibiting 
vitamin K dependent clotting factors (II, VII, IX, and 
X). 
Warfarin has a narrow therapeutic index and 
therefore monitoring is essential.  
• Low Molecular weight heparin (LMWH) 
LMWH also works by inhibiting various clotting 
factors. It is given subcutaneously and therefore 
more commonly used either during initial treatment of 
VTE or when NOACs or warfarin are contraindicated. 
• Other types of treatment  
Other treatments include the inferior vena cava filter, 
thrombolysis and thrombectomy but are uncommon, 
typically reserved for severe risk factors or contra-
indications to treatment.  Within aviation, the 
underlying reason for using these treatments may be 
incompatible with continued certification. In addition, 
there is a risk of thrombosis with the use of filters 
which could also be considered incompatible with 
ongoing certification6. 
 
EFFECTS OF AVIATION ENVIRONMENT ON THE 
CONDITION AND TREATMENT 
 
Multiple aspects within the aviation environment are 
thought to contribute to the development of venous 
thromboembolism.  
Looking specifically at Virchows triad and the 
associated aviation factors. 
Venous Stasis 
• Immobility – long periods of immobility in any 
form of travel can increase risk of VTE. 
 
Flight duration is recognised to be a risk factor in 
PE/DVT with flights greater than 4 hours having an 
absolute risk of a symptomatic event if 1 in 4600 
flights7. In addition, Lapostolle et al found that the 
incidence of pulmonary emboli increased with 
distance travelled (0.01 case per million <5000km 
compared to 4.8 cases per million > 10 000km)8, 9.  
Although the general public often call VTE in travel 
“economy class syndrome”, the class of travel has 
been found not to be a factor in the development of 
thrombosis10, 11. 
• Fluid retention with lower leg oedema12   
 
Hypercoagulability 
• Dehydration - reduced fluid intake and reduced 
cabin humidity resulting in haemoconcentration 
thereby increasing blood viscosity and reduced 
flow13.  
• Increased erythropoietin – Gunga et al noted 




• Hypoxia due to hypobaric conditions can cause 
endothelial injury and activate the coagulation 
pathway15   
Interestingly, although long-haul travel is associated 
with increased risk of DVT in the general population, 
this has not been found in the pilot population.  A 
study published in 2014 found that the incidence of 
VTE was not increased amongst the pilot population; 
this was postulated to be due to the “healthy worker 
effect” amongst aviators16. 
 
EFFECT OF THE CLINICAL CONDITION ON FUNCTIONAL 
CAPABILITY 
 
• Overt incapacitation from sudden death or 
syncope 
Untreated pulmonary embolism has a significant risk 
of mortality, estimated to be 26 to 30%17, with 10% of 
acute PEs dying within 2 hours18.  
• Subtle incapacitation due to distraction from 
symptoms such as dyspnoea, chest pain, 
haemoptysis, leg pain, dizziness. 
Although it can be assumed that not all DVTs will be 
incapacitating, it is important to acknowledge that all 
PEs will have the risk of incapacitation and therefore 
the risk of developing a PE needs to be considered.  
Unfortunately it is difficult to estimate this risk.   A 
meta-analysis by Wu et al found that the incidence of 
 
PE in patients with a symptomatic calf DVT ranged 
from 0 to 6.2% however, other studies have found 
that a silent PE in up to 50% of patients with a DVT19, 
18, 20,21. 
Furthermore, the risk of recurrence of VTE must also 
be considered. It is now recognised that the risk of 
recurrence is higher than previously assumed with 
strong risk factors including an unprovoked VTE, PE, 
persistent risk factor such as active cancer, anti-
phospholipid syndrome, anti-thrombin, protein C or S 
deficiency. Other thrombophilia disorders such as 
Factor V Leiden are no longer thought to have an 
effect on recurrence5.  
Recurrence of VTE as per Thrombosis and 
Haemostasis Society of Australia and NZ Guidelines5  
For a provoked distal VTE, unprovoked, the 
recurrence at 1 year post ceasing anticoagulation 
and at 5 years is 5% and 15% respectively.  For a 
proximal DVT or PE this increases to 10% and 30% 
respectively.  For a second episode of unprovoked 
VTE the risk increases to 15% at 1 year and 45% at 
5 years.   
For a provoked VTE due to surgery or cancer, in 
comparison, the risk is 1% at 1 year and 3% at 5 
years which fits within aeromedical risk guidelines 
such as the 1% rule. 
 
EFFECT OF TREATMENT OF CLINICAL CONDITION ON 
FUNCTIONAL CAPABILITY 
 
• Incapacitation due to side-effects of medication 
such as major haemorrhage  
The main concern with treatment is the risk of 
haemorrhage. 
The International Society of Thrombosis and 
Haemostasis classify bleeding risk as major bleeding, 
clinically relevant non-major bleeding and minor 
bleeding22, 23.  
Major bleeding defined as: 
• Fatal bleeding and/or; 
• Symptomatic bleeding in a critical area or organ 
such as intracranial, intraspinal, intraocular, 
retroperitoneal, intraarticular or pericardial, or 
intramuscular with compartment syndrome 
and/or; 
• Bleeding causing a fall in haemoglobin level of 
2g/dL or more, or leading to transfusion of two or 
more units of while blood or red cells. 
Within clinical studies, it is the major bleeding which 
would be considered aeromedically significant. 
It is generally well accepted that risk of bleeding in 
otherwise healthy individuals on lower dose NOACs 
is lower that previously thought. 
The AMPLIFY-EXT study looked at apixaban, 
compared to placebo and found that the risk of 
recurrence of symptomatic VTE occurred in 1.7% of 
both higher (5mg bd) and lower (2.5mg bd) of 
apixaban compared to 8.8% recurrence in placebo. 
The rate of major bleeding in the placebo group was 
0.5% with 0.1% in the 5-mg apixaban group and 
0.2% in the 2.5mg apixaban group24. 
The EINSTEIN CHOICE study in 2017 compared 
rivaroxaban to aspirin in VTE found that recurrence 
was reduced in the rivaroxaban groups compared to 
those receiving aspirin, without a significant increase 
in bleeding25. Major bleeding occurred in 0.5% of the 
20mg od rivaroxaban group, 0.4% in 10mg od and 
0.3% in the aspirin group. Recurrence rates were 
1.5% in 20mg rivaroxaban group, 1.2% in the 10mg 
group and 4.4% in the aspirin group. 
 Recurrence Major 
bleed 
Rivaroxaban 10mg od 1.2% 0.4% 
Rivaroxaban 20mg od 1.5% 0.5% 
Aspirin 100mg od 4.4% 0.4% 
Apixaban 2.5mg bd 1.7% 0.2% 
Apixaban 5mg bd 1.7% 0.1% 
Placebo 8.8% 0.5% 
 
Furthermore, a large meta-analysis by Wang et al in 
2018 found that Vitamin K antagonists were 
associated with low rates of recurrence of VTE (0.15-
0.23) however, higher risks of major bleeding (4.14-
4.42)26. This is in keeping with a study by van Es et al 
who found similar efficacy in preventing VTE 
recurrence between NOACs and Vitamin K 
antagonists however risk of bleeding in NOACs was 
significantly less with a relative risk of 0.6127. 
 
REGULATORY ADVICE - NOACs 
Internationally, ICAO Annex 1 Chapter 6 states28:  
“An applicant for any class of Medical Assessment 
shall be required to be free from: 
d) any effect or side-effect of any prescribed or non-
prescribed therapeutic, diagnostic or preventative 
medication taken;” 
 
“6.3.2.8 There shall be no significant functional nor 
structural abnormality of the circulatory system.” 
“6.3.2.17 Applicants with diseases of the blood 
and/or the lymphatic system shall be assessed as 
unfit unless adequately investigated and their 
condition found unlikely to interfere with the safe 
exercise of their licence and rating privileges.” 
Australia29  
If an applicant is stable, on an oral anti-coagulant, 
then the clinical practice guidelines for CASA state 
that Class 1 and Class 3 applicants will be restricted 
to either multi-crew or proximity restrictions. 
However, applicants may be individually assessed 
regarding these restrictions. 
New Zealand CAA30 
The NZ CAA advise that an applicant who is currently 
treated with anticoagulants would be considered 
safety relevant. 
Specifically for NOACs, if the applicant is free of side-
effects, they may be issued a certificate however, 
those with a Class 1 would have the following 
restriction “not valid for single pilot air operations 
carrying passengers”  
UKCAA31 
The UK CAA look at NOACs on a case by case basis 
but generally advise that dabigatran, rivaroxaban and 
apixaban are acceptable and that pilots should be 




When considering the aeromedical significance of 
VTE, it is important to consider the underlying reason 
for the episode and the treatment.  
The current evidence shows that the risk of major 
bleeding on NOACs are low with studies revealing a 
<1% risk; this can be considered acceptable within 
aviation.  
In addition, the risk of recurrence of VTE may be 
higher than 1% however, as discussed above, not all 
VTEs will be incapacitating.  
For example, a patient with a PE will have a 
recurrence risk of 30% at 5 years = 6%pa, which 
would be unacceptable for many regulators. 
If, however this applicant is treated with a long term 
low dose NOAC (e.g. apixaban 2.5mg bd) then the 
risk of recurrence would be 1.7% but incapacitation 
risk can be considered to be 50% of this i.e 0.85%.  
In addition, the risk of major bleed would be 0.2%pa. 
It would be reasonable to conclude that this applicant 
can be considered safe to fly without any restrictions, 
based on the combination of the recurrence and 
treatment risks.  
Medicine is ever changing, and it is important as 
aeromedical examiners and regulators, to continue to 
review medical literature in order to apply up to date 
reasoned, evidence based aeromedical decision 
making. 
VTE is one such condition where over time, studies 
with respect to novel treatments have provided more 
reassuring risk profiles that may allow more 
favourable certification outcomes. 
The views expressed in this paper are those of the 
author and do not reflect CASA policy 
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